Literature DB >> 2399936

Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations.

A J Demetris1, S Todo, D H Van Thiel, J J Fung, Y Iwaki, G Sysyn, W Ming, J Trager, T E Starzl.   

Abstract

The morphologic evolution of hepatitis B virus (HBV) liver disease in 45 hepatic allograft recipients who were HBV surface-antigen positive (HBs-Ag+) at the time of liver replacement and who survived for more than 60 days was studied by routine histologic and immunocytochemical analysis of serial pathology specimens. The findings in these patients were compared to a control group of 30 individuals who were immune to the HBV (anti-HBs antibody positive), but required hepatic replacement for other reasons. Eight of the forty-five (18%) HBsAg-positive patients have no serologic evidence of HBV reinfection after transplantation. All 37 remaining patients are reinfected; 21 (47%) developed chronic active hepatitis and/or cirrhosis, 3 (7%) developed submassive necrosis, and 6 (14%) developed chronic lobular hepatitis. One patient lost her graft to chronic rejection, despite reinfection with the B virus. Four other patients (9%) developed a chronic carrier state. No long-term follow-up biopsies were available in the remaining two patients. The histologic features associated with dysfunction related to recurrent HBV infection evolved from an acute to chronic phase and were similar to hepatitis B seen in nonallografted livers. Furthermore HBV-related lesions could be separated from rejection using routine histology alone. The only exception to this conclusion was the occurrence of a peculiar HBV-related lesion in two recipients, described herein. Immunohistochemical analysis demonstrated the presence of viral antigens in almost all cases. Hepatic inflammation also was commonly present during HBV disease and consisted mostly of accessory cells and T lymphocytes. Analysis of the effect of major histocompatibility complex matching revealed no clear association between the number of class I or II matches or mismatches and the development, or pattern, of active hepatitis in the allograft. Peculiar pathologic alterations in several of the biopsies and failed allografts after HBV reinfection suggests that, under special circumstances, the B virus may be cytopathic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2399936      PMCID: PMC1877527     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  12 in total

1.  Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin.

Authors:  P J Johnson; M H Wansbrough-Jones; B Portmann; A L Eddleston; R Williams; W D Maycook; R Y Calne
Journal:  Br Med J       Date:  1978-01-28

Review 2.  Hepatitis B virus structure and biology.

Authors:  F V Chisari; C Ferrari; M U Mondelli
Journal:  Microb Pathog       Date:  1989-05       Impact factor: 3.738

3.  Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months.

Authors:  N J Feduska; J Melzer; W J Amend; F Vincenti; S Tomlanovich; O Salvatierra
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

Review 4.  Molecular and cellular pathology of hepatitis B.

Authors:  M A Gerber; S N Thung
Journal:  Lab Invest       Date:  1985-06       Impact factor: 5.662

5.  Liver transplantation in patients with B viral hepatitis and delta infection.

Authors:  M Colledan; M Gislon; M Doglia; L R Fassati; G Ferla; B Gridelli; G Rossi; D Galmarini
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts.

Authors:  W Lauchart; R Müller; R Pichlmayr
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection.

Authors:  A J Demetris; R Jaffe; D G Sheahan; J Burnham; J Spero; S Iwatsuki; D H Van Theil; T E Starzl
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

8.  Liver transplantation in hepatitis delta virus disease.

Authors:  M Rizzetto; S Macagno; E Chiaberge; G Verme; F Negro; G Marinucci; C di Giacomo; D Alfani; R Cortesini; F Milazzo
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

9.  Liver allograft. Its use in chronic active hepatitis with macronodular cirrhosis, hepatitis B surface antigen.

Authors:  J L Corman; C W Putnam; S Iwatsuki; A G Redeker; K A Porter; R L Peters; G Schröter; T E Starzl
Journal:  Arch Surg       Date:  1979-01

10.  HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: its role in the pathogenesis of chronic type B hepatitis.

Authors:  C M Chu; W C Shyu; R W Kuo; Y F Liaw
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

View more
  22 in total

1.  Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine.

Authors:  D H Van Thiel; H I Wright; J S Gavaler; J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Liver transplantation--challenges for the future.

Authors:  E B Keeffe
Journal:  West J Med       Date:  1991-11

3.  Hepatitis B virus infection and liver transplantation.

Authors:  N A Terrault; T L Wright
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

Review 4.  Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation.

Authors:  M T LaRocco; S J Burgert
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 5.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

6.  Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon.

Authors:  A Jain; A J Demetris; R Manez; A C Tsamanadas; D Van Thiel; J Rakela; T E Starzl; J J Fung
Journal:  Liver Transpl Surg       Date:  1998-05

Review 7.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

8.  Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation.

Authors:  O Bronsther; R Mañez; S Kusne; W Irish; W Roland; A Jain; R Llull; A J Demetris; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

9.  Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis.

Authors:  A J Demetris; B Eghtesad; A Marcos; K Ruppert; M A Nalesnik; P Randhawa; T Wu; A Krasinskas; P Fontes; T Cacciarelli; A O Shakil; N Murase; J J Fung; T E Starzl
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

10.  Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.

Authors:  Shu-Yuan Xiao; Liang Lu; Hanlin L Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.